Get the Stockscreener App
1.54
3.14%
-0.05
Akebia Therapeutics Inc stock is traded at $1.54, with a volume of 3.91M.
It is down -3.14% in the last 24 hours and down -51.27% over the past month.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
See More
Previous Close:
$1.59
Open:
$1.62
24h Volume:
3.91M
Relative Volume:
0.92
Market Cap:
$408.32M
Revenue:
$194.75M
Net Income/Loss:
$-51.26M
P/E Ratio:
-5.50
EPS:
-0.28
Net Cash Flow:
$-23.38M
1W Performance:
-12.50%
1M Performance:
-51.27%
6M Performance:
-47.26%
1Y Performance:
-13.97%
1-Day Range:
$1.525
$1.6555
1-Week Range:
$1.525
$1.835
52-Week Range:
$1.52
$4.0787
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Name
Akebia Therapeutics Inc
Sector
Phone
617-871-2098
Address
245 FIRST STREET, CAMBRIDGE, MA
Compare AKBA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
1.54 | 421.93M | 194.75M | -51.26M | -23.38M | -0.28 |
|
ZTS
Zoetis Inc
|
115.89 | 51.60B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.51B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.60 | 42.35B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
24.28 | 28.04B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
474.72 | 20.52B | 3.08B | 1.24B | 1.07B | 25.61 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-04-25 | Resumed | H.C. Wainwright | Buy |
| Apr-28-25 | Initiated | Leerink Partners | Outperform |
| Apr-01-25 | Initiated | Jefferies | Buy |
| Nov-29-23 | Resumed | BTIG Research | Buy |
| Aug-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-31-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-31-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-31-22 | Downgrade | Mizuho | Buy → Neutral |
| Mar-31-22 | Downgrade | Needham | Buy → Hold |
| Mar-31-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-14-19 | Reiterated | Needham | Buy |
| Aug-06-19 | Reiterated | H.C. Wainwright | Buy |
| Jul-11-19 | Reiterated | H.C. Wainwright | Buy |
| May-02-19 | Initiated | JP Morgan | Overweight |
| Mar-20-19 | Initiated | Citigroup | Neutral |
| Sep-07-18 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-10-18 | Reiterated | Needham | Buy |
| Jun-06-18 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-17 | Initiated | Piper Jaffray | Overweight |
| Dec-07-17 | Initiated | BTIG Research | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-10-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-27-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-27-17 | Reiterated | Needham | Buy |
| Dec-27-16 | Reiterated | H.C. Wainwright | Buy |
| Dec-20-16 | Reiterated | JMP Securities | Mkt Outperform |
| Nov-15-16 | Initiated | Aegis Capital | Buy |
| Sep-29-16 | Initiated | Brean Capital | Buy |
| Mar-16-16 | Reiterated | Needham | Buy |
| Jan-21-16 | Initiated | Credit Suisse | Neutral |
View All
Akebia Therapeutics Inc Stock (AKBA) Latest News
How forex fluctuations impact Akebia Therapeutics Inc. (AX9) stockWeekly Loss Report & Reliable Intraday Trade Plans - newser.com
How Akebia Therapeutics Inc. stock compares to market leadersPortfolio Risk Summary & Growth Focused Entry Point Reports - newser.com
What analyst consensus implies for Akebia Therapeutics Inc. (AX9) stockCEO Change & AI Forecasted Entry/Exit Points - newser.com
Is Akebia Therapeutics Inc. stock cheap at current valuationBond Market & Weekly High Potential Stock Alerts - newser.com
Live market analysis of Akebia Therapeutics Inc.Portfolio Gains Report & Real-Time Sentiment Analysis - newser.com
How Akebia Therapeutics Inc. (AX9) stock gains from tech spendingTrade Entry Report & Free Verified High Yield Trade Plans - newser.com
How Akebia Therapeutics Inc. (AX9) stock behaves in tightening cyclesMarket Volume Summary & Expert Curated Trade Setups - newser.com
Signal strength of Akebia Therapeutics Inc. stock in tech scannersJuly 2025 Opening Moves & Low Risk Entry Point Guides - newser.com
Is Akebia Therapeutics Inc. stock a safe investment in uncertain markets2025 AllTime Highs & Low Drawdown Investment Strategies - newser.com
How strong dollar benefits Akebia Therapeutics Inc. (AX9) stock - newser.com
Tools to assess Akebia Therapeutics Inc.’s risk profileJuly 2025 Weekly Recap & Stock Portfolio Risk Control - newser.com
Brokerages Set Akebia Therapeutics, Inc. (NASDAQ:AKBA) Price Target at $6.00 - Defense World
This trade activity should not be overlooked: Akebia Therapeutics Inc (AKBA) - Setenews
Levi & Korsinsky Announces an Investigation on Behalf of Akebia Therapeutics, Inc. (AKBA) Shareholders Who May Have Been Affected by Fraud - ACCESS Newswire
AKBA: Vafseo's expanding access and strong clinical data position it for standard of care in dialysis - TradingView
Akebia Therapeutics, Inc. Announces Amendment to License Agreement for Drug Supply and Manufacturing Rights - MarketScreener
Akebia Therapeutics amends license agreement with Medice for Vafseo supply - Investing.com
Akebia Therapeutics amends license agreement with Medice for Vafseo supply By Investing.com - Investing.com South Africa
Akebia Therapeutics Inc says on Nov 12, co and Medice amend license agreement - MarketScreener
Analyzing Akebia Therapeutics Inc. with risk reward ratio charts2025 Trading Recap & Reliable Breakout Stock Forecasts - newser.com
Akebia Therapeutics Shares Extend Decline Amid Analyst Downgrades - Ad-hoc-news.de
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
FY2025 Earnings Forecast for AKBA Issued By Leerink Partnrs - MarketBeat
Akebia Therapeutics Inc. stock retracement – recovery analysisMarket Performance Recap & Growth Oriented Trading Recommendations - newser.com
Shareholders Alert: Investigation Into Akebia Therapeutics, Inc. (AKBA)Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
How Akebia Therapeutics Inc. stock reacts to job market data2025 Price Targets & Community Consensus Picks - newser.com
Why Akebia Therapeutics Inc. (AX9) stock attracts wealthy investorsExit Point & AI Driven Price Predictions - newser.com
How rising interest rates impact Akebia Therapeutics Inc. stockQuarterly Profit Report & Accurate Technical Buy Alerts - newser.com
Akebia Therapeutics Inc Stock (AKBA) Financials Data
Revenue
Net Income
Cash Flow
EPS
6.17%
0.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):